AI-based CAD software enhances radiologists' performance to interpret ABUS images

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-10-11 14:30 GMT   |   Update On 2023-10-11 14:30 GMT

A recent study has demonstrated the potential of artificial intelligence (AI)-based computer-aided detection software (CAD) to significantly improve the diagnostic performance of radiologists in detecting suspicious breast lesions through automated breast ultrasounds (ABUS). The findings suggest that AI-CAD could become a valuable diagnostic tool for improving breast cancer...

Login or Register to read the full article

A recent study has demonstrated the potential of artificial intelligence (AI)-based computer-aided detection software (CAD) to significantly improve the diagnostic performance of radiologists in detecting suspicious breast lesions through automated breast ultrasounds (ABUS). The findings suggest that AI-CAD could become a valuable diagnostic tool for improving breast cancer detection.

Breast cancer remains a significant global health concern, and early detection is crucial for improving patient outcomes. Mammography is the standard screening tool, but automated breast ultrasounds (ABUS) are increasingly utilized for breast lesion detection. The study aimed to assess the impact of AI-CAD on radiologists' performance in detecting breast lesions and reclassifying Breast Imaging Reporting and Data System (BI-RADS) categories.

This study was published in Academic Radiology by Kwon M. and colleagues. The study included 262 breast lesions detected via ABUS, with histopathological verification between January 2020 and December 2022. Two radiologists independently reviewed the images and assigned BI-RADS categories. AI-CAD software was employed to classify ABUS images as positive or negative for suspicious lesions. Four approaches were used to readjust the BI-RADS categories: radiologists modified categories based on AI results (AI-aided 1), upgraded or downgraded based on AI results (AI-aided 2), only upgraded for positive AI results (AI-aided 3), or only downgraded for negative AI results (AI-aided 4). The diagnostic performance of AI-aided approaches was compared to radiologists. Additionally, characteristics of AI-CAD-positive and AI-CAD-negative cancer cases were examined.

  • The study included 262 lesions from 231 women, including 145 malignant and 117 benign cases, with a mean age of 52.2 years.
  • The area under the receiver operator characteristic curve (AUC) for radiologists was 0.870 (95% confidence interval [CI], 0.832–0.908).
  • AI-CAD implementation significantly improved radiologists' performance, with AI-aided 1 achieving an AUC of 0.919 (95% CI, 0.890–0.947; P = 0.001).
  • AI-aided 2, 3, and 4 also demonstrated improvements in AUC, although without statistical significance.
  • AI-CAD-negative cancer cases tended to be smaller, less frequently exhibited a retraction phenomenon, and had lower BI-RADS categories.
  • Among non mass lesions, AI-CAD-negative cancers showed no posterior shadowing.

The study highlights the potential of AI-CAD as a powerful tool to enhance the diagnostic capabilities of radiologists in detecting breast lesions using ABUS. The implementation of AI significantly improved diagnostic performance, which could contribute to more accurate and efficient breast cancer detection. These findings offer promising prospects for the integration of AI technology in breast cancer screening and diagnosis.

Reference:

Kwon, M.-R., Youn, I., Lee, M. Y., & Lee, H.-A. Diagnostic performance of artificial intelligence–based computer-aided detection software for automated breast ultrasound. Academic Radiology,2023. https://doi.org/10.1016/j.acra.2023.09.013 

Tags:    
Article Source : Academic Radiology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News